Search hospitals > Tennessee > Kingsport

Wellmont Holston Valley Hospital and Medical Center

Claim this profile
Kingsport, Tennessee 37660
Global Leader in Type 2 Diabetes
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Coronary Artery Disease
121 reported clinical trials
4 medical researchers
Photo of Wellmont Holston Valley Hospital and Medical Center in KingsportPhoto of Wellmont Holston Valley Hospital and Medical Center in KingsportPhoto of Wellmont Holston Valley Hospital and Medical Center in Kingsport

Summary

Wellmont Holston Valley Hospital and Medical Center is a medical facility located in Kingsport, Tennessee. This center is recognized for care of Type 2 Diabetes, Breast Cancer, Breast cancer, Lung Cancer, Coronary Artery Disease and other specialties. Wellmont Holston Valley Hospital and Medical Center is involved with conducting 121 clinical trials across 281 conditions. There are 4 research doctors associated with this hospital, such as Asheesh Shipstone, Joseph Ley, Morawski, and Emily Morawski, MD.

Area of expertise

1Type 2 Diabetes
Global Leader
Wellmont Holston Valley Hospital and Medical Center has run 33 trials for Type 2 Diabetes.
2Breast Cancer
Global Leader
Wellmont Holston Valley Hospital and Medical Center has run 18 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at Wellmont Holston Valley Hospital and Medical Center

Lung Cancer
Cancer
Bladder Cancer
Breast Cancer
Lymphoma
Breast cancer
Non-Small Cell Lung Cancer
Urothelial Carcinoma
ALK Gene Rearrangement
Chronic Lymphocytic Leukemia
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Wellmont Holston Valley Hospital and Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security